

The covid situation at Uppsala University Hospital affects the start of the NEX-18 phase Ia study

Nanexa's planned phase Ia study in the NEX-18 project was set to start on April 15. The clinic at Uppsala University hospital informed Nanexa last Friday that their staff need to be used in other departments for covid care, and therefore, the study can not be started as planned on the 15th. The company is in close contact with the clinic to find the quickest solution possible. On Nanexa's other study site, at the Karolinska University Hospital in Huddinge, preparations are ongoing and the study is expected to start according to plan by end of April.

"We would of course have wished to start the study both in Uppsala and Huddinge according to plan, but at the same time, we fully understand the priorities of Uppsala University Hospital in favor of the covid care, there is no doubt about that. We are now in discussions to see if Huddinge, instead, can take a larger part of the study. It remains to be seen if this delay will affect the time for final study results. We have a very good collaboration with both clinics and know that they will do what it takes to complete the study as soon and as quickly as possible", says David Westberg, CEO of Nanexa.

For additional information, please contact:

David Westberg – CEO, Nanexa AB (publ)

Phone: +46 70 942 83 03

Email: david.westberg@nanexa.se

www.nanexa.com

Erik Penser Bank is the company's Certified Adviser and can be reached on +46 8 463 83 00, email: certifiedadviser@penser.se

About Nanexa AB (publ)

Nanexa AB is a nanotechnology drug delivery company focusing on the development of PharmaShell®, a new and groundbreaking drug delivery system with great potential in a number of medical indications. Within the framework of PharmaShell®, Nanexa has partnership agreements with among others, AstraZeneca.

Attachments

[The covid situation at Uppsala University Hospital affects the start of the NEX-18 phase Ia study](#)